

Pharmacy Medical Necessity Guidelines: Cosentyx® (secukinumab)

Effective: July 10, 2018

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
<p>This Pharmacy Medical Necessity Guideline applies to the following:</p> <p>Tufts Health Plan Commercial Plans</p> <input type="checkbox"/> Tufts Health Plan Commercial Plans – large group plans <input type="checkbox"/> Tufts Health Plan Commercial Plans – small group and individual plans <p>Tufts Health Public Plans</p> <input type="checkbox"/> Tufts Health Direct – Health Connector <input checked="" type="checkbox"/> Tufts Health Together – A MassHealth Plan <input type="checkbox"/> Tufts Health RITogether – A RItE Care + Rhody Health Partners Plan <p>Tufts Health Freedom Plan products</p> <input type="checkbox"/> Tufts Health Freedom Plan - large group plans <input type="checkbox"/> Tufts Health Freedom Plan - small group plans		<p>Fax Numbers:</p> <p>RXUM: 617.673.0988</p>	

OVERVIEW

FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

Cosentyx (secukinumab) is a human interleukin-17A antagonist indicated for:

- **Ankylosing Spondylitis:**
Treatment of adult patients with active ankylosing spondylitis.
- **Plaque psoriasis:**
Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
- **Psoriatic Arthritis:**
Treatment of adult patients with active psoriatic arthritis.

COVERAGE GUIDELINES

The plan may authorize coverage of Cosentyx (secukinumab) for Members when all of the following criteria for a particular regimen are met and limitations do not apply:

Ankylosing Spondylitis

1. The Member has a documented definitive diagnosis of active ankylosing spondylitis from a rheumatologist
- AND**
2. The Member is 18 years of age or older
- AND**
3. The Member has tried and failed treatment with, or the Member has a contraindication to at least one NSAID
- AND**
4. The Member has tried and failed treatment with, or the provider has indicated clinical inappropriateness of treatment with Humira and Enbrel

Plaque Psoriasis

1. The Member has a documented definitive diagnosis from a dermatologist of moderate to severe chronic plaque psoriasis
- AND**
2. The Member is 18 years of age or older
- AND**
3. The Member has tried and failed treatment with, or the Member has a contraindication to, at least 2 of the preferred therapies, such as PUVA or UVB phototherapy, acitretin, cyclosporine or methotrexate
- AND**
4. The Member has tried and failed treatment with, or the provider has indicated clinical inappropriateness of treatment with Humira and Enbrel

Psoriatic Arthritis

1. The Member has a documented definitive diagnosis of active psoriatic arthritis from a rheumatologist
- AND**
2. The Member is 18 years of age or older
- AND**
3. The Member has a documented inadequate response or inability to take methotrexate OR sulfasalazine at maximal doses for three months.
- AND**
4. The Member has tried and failed treatment with, or the provider has indicated clinical inappropriateness of treatment with Humira and Enbrel

Note: Maximal doses of methotrexate are defined as 15mg to 25mg per week depending on the patient's tolerance.

LIMITATIONS

1. Samples, free goods or similar offerings of Cosentyx (secukinumab) do not qualify for an established clinical response and will not be considered for prior authorization.
2. Members new to the plan and stable on Cosentyx (secukinumab) are not required to provide documentation of prerequisite trials with conventional (i.e., non-biologic) therapies (e.g., methotrexate, NSAID, sulfasalazine).
3. For the diagnosis of plaque psoriasis, inconvenience does not qualify as a contraindication to phototherapy.
4. Documentation of a Member being a social drinker does not qualify as a medically acceptable contraindication or clinically inappropriateness to methotrexate therapy.
5. Coverage for Cosentyx (secukinumab) for the diagnosis of ankylosing spondylitis will be limited to 28-day supplies as follows:
Initial prescription:
 - 150 mg dose
 - Four cartons (4 doses) of one 150 mg/mL Sensoready pen **OR**
 - Four cartons (4 doses) of one 150 mg/mL single-use prefilled syringe
Followed by:
 - 150 mg dose
 - One carton of one 150 mg/mL Sensoready pen per 28 days **OR**
 - One carton of one 150 mg/mL single-use prefilled syringe per 28 days
6. For the diagnosis of active psoriatic arthritis, the Plan requires documentation of a therapeutic failure (i.e., the member continues to have active psoriatic arthritis) on Cosentyx 150 mg every 4 weeks before the 300 mg dose may be approved.
7. Coverage for Cosentyx (secukinumab) for the diagnoses of plaque psoriasis and psoriatic arthritis will be limited to 28-day supplies as follows:
Initial prescription:
 - 150 mg dose
 - Four cartons (4 doses) of one 150 mg/mL Sensoready pen **OR**
 - Four cartons (4 doses) of one 150 mg/mL single-use prefilled syringe
 - 300 mg dose
 - Four cartons of two 150 mg/mL (300 mg dose) Sensoready pens **OR**
 - Four cartons of two 150 mg/mL (300 mg dose) single-use prefilled syringes
Followed by:
 - 150 mg dose
 - One carton of one 150 mg/mL Sensoready pen per 28 days **OR**
 - One carton of one 150 mg/mL single-use prefilled syringe per 28 days
 - 300 mg dose
 - One carton of two 150 mg/mL (300 mg dose) Sensoready pens per 28 days **OR**
 - One carton of two 150 mg/mL (300 mg dose) single-use prefilled syringes

CODES

Medical billing codes may not be used for this medication. This medication must be obtained via the Member's pharmacy benefit.

REFERENCES

1. Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013 Nov 23;382(9906):1705-13.
2. Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med*. 2015 Dec 24;373(26):2534-48.
3. Bhosle M, Kulkarni A, Feldman SR et al. Quality of life in patients with psoriasis. *Health Qual Life Outcomes*. 2006;4:35.
4. Blauvelt A, Prinz J, Gottlieb A et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). *Br J Dermatol* 2015;172(2):484-93.
5. Callen JP, Krueger GG, Lebwohl M et al. AAD consensus statement on psoriasis therapies. *J Am Acad Dermatol*. 2003; 49:897-9.
6. Cosentyx prescribing information. East Hanover, New Jersey: Novartis Pharmaceuticals; 2018 January.
7. Enbrel prescribing information. Thousand Oaks, CA: Amgen Inc. and Pfizer Inc.; 2015 March.
8. Farahnik B, Beroukhir K, Zhu TH et al. Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. *Dermatol Ther*. 2016 Mar;6(1):25-37.
9. Food and Drug Administration. Drugs@FDA. URL: accessdata.fda.gov/scripts/cder/drugsatfda. Available from Internet. Accessed 2015 June 12.
10. Gisondi P, Fantin F, Del Giglio M et al. Chronic plaque psoriasis is associated with increased arterial stiffness. *Dermatology*. 2009; 218(2):110-3.
11. Gisondi P, Galvan A, Idolazzi L et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities. *Front Med*. 2015 ;2:1.
12. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*. 2015 Dec 7
13. Gottlieb AB, Langley RG, Philipp S, et al. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. *J Drugs Dermatol*. 2015 Aug;14(8):821-33.
14. Humira prescribing information. North Chicago, IL: AbbVie Inc.; 2016 June.
15. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. *J Am Acad Dermatol*. 2005; 53(1 Suppl 1):S94-100.
16. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. *N Engl J Med*. 2014;371(4):326-38.
17. Lebwohl M. Psoriasis. *Lancet*. 2003; 361(9364):1197-204.
18. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. *Annu Rev Immunol*. 2014;32:227-55.
19. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. *Br J Dermatol*. 2002; 146(3):351-64.
20. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015 Sep 19;386(9999):1137-46.
21. Menter A, Korman N, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011; 65(1):137-74.
22. Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). *J Am Acad Dermatol*. 2015 Jul;73(1):27-36.e1.
23. National Psoriasis Foundation. About psoriasis. URL: psoriasis.org/about-psoriasis. Available from Internet. Accessed 2016 August 5.
24. Novartis. Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx to Stelara in clearing skin. 2014. URL: novartis.com/news/media-releases/head-head-psoriasis-study-demonstrates-superiority-novartis-cosentyx-stelara%20AE. Available from Internet. Accessed 2015 June 22.
25. Novartis. New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients. 2015. URL: novartis.com/news/media-releases/new-novartis-data-shows-cosentyx-significantly-superior-stelara%20AE-and-clears. Available from Internet. Accessed 2015 June 22.

26. Paul C, Lacour JP, Tedremets L et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). *J Eur Acad Dermatol Venereol*. 2015 Jun;29(6):1082-90.
27. Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*. 2015 Dec 11.
28. Taçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. *J Am Acad Dermatol*. 2015 Sep;73(3):400-9.
29. Taçi D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). *Br J Dermatol*. 2015 Sep;173(3):777-87.
30. Ungprasert P, Thongprayoon C, Davis JM 3rd. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis. *Semin Arthritis Rheum*. 2015 Oct 3.
31. Xiong HZ, Gu JY, He ZG, Chen WJ, Zhang X, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. *Int J Clin Exp Med*. 2015;8(3):3156-72.

APPROVAL HISTORY

July 14, 2015: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

- January 1, 2016: Administrative change to rebranded template.
- February 9, 2016: Effective April 1, 2016, added pharmacy coverage guidelines for indications ankylosing spondylitis and psoriatic arthritis.
- September 13, 2016: No changes
- April 11, 2017: Administrative update, Adding Tufts Health RITogether to the template.
- July 11, 2017: Administrative update to add the following Limitation: Samples, free goods or similar offerings of Cosentyx (secukinumab) do not qualify for an established clinical response and will not be considered for prior authorization.
- December 12, 2017: Effective January 1, 2018, removed criteria allowing members new to the plan stable on Cosentyx (secukinumab) to be authorized due to new state requirements. Added the following limitation: Members new to the plan and stable on Cosentyx (secukinumab) are not required to provide documentation of prerequisite trials with conventional (i.e., non-biologic) therapies (e.g., methotrexate, NSAID, sulfasalazine).
- May 8, 2018: Administrative update to add the following Limitations: For the diagnosis of plaque psoriasis, inconvenience does not qualify as a contraindication to phototherapy and documentation of a Member being a social drinker does not qualify as a medically acceptable contraindication or clinically inappropriateness to methotrexate therapy.

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. They are used in conjunction with a Member's benefit document and in coordination with the Member's physician(s). The plan makes coverage decisions on a case-by-case basis considering the individual Member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

This Pharmacy Medical Necessity Guideline does not apply to Uniformed Services Family Health Plan Members or to certain delegated service arrangements. Unless otherwise noted in the Member's benefit document or applicable Pharmacy Medical Necessity Guideline, Pharmacy Medical Necessity Guidelines do not apply to CareLinkSM Members. For self-insured plans, drug coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a coverage guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern. Applicable state or federal mandates will take precedence.

For Tufts Health Plan Medicare Preferred, please refer to Tufts Health Plan Medicare Preferred Prior Authorization Criteria.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to Member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.

[Provider Services](#)